Literature DB >> 16567591

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload.

Yasuhiro Izumiya1, Ichiro Shiojima, Kaori Sato, Douglas B Sawyer, Wilson S Colucci, Kenneth Walsh.   

Abstract

Cardiac hypertrophy is associated with upregulation of vascular endothelial growth factor (VEGF) in the myocardium. Here, we evaluated the effects of a decoy VEGF receptor on heart morphology and function to a murine model of pressure overload hypertrophy. Mice were administered adenoviral vector encoding a decoy VEGF receptor (Ad-Flk), and their hearts were subjected to pressure overload by transverse aortic constriction (TAC). Treatment with Ad-Flk led to a net reduction in capillary density in hearts subjected to TAC. Ad-Flk also led to a reduction in TAC-induced cardiac hypertrophy and promoted left ventricle dilatation and a loss in contractile function. Treatment with Ad-Flk markedly increased myocardial fibrosis and collagen gene upregulation. In contrast, Ad-Flk had no effect on any of these parameters in sham-treated mice. Administration of a VEGF trap reagent diminished pressure overload cardiac hypertrophy and promoted the progression to heart failure but had no effect on sham-treated animals. These findings suggest that VEGF is required to maintain myocardial capillary density and that reductions in the vascular bed are associated with the transition from compensatory hypertrophy to failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567591      PMCID: PMC3132898          DOI: 10.1161/01.HYP.0000215207.54689.31

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  43 in total

1.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.

Authors:  P Carmeliet; Y S Ng; D Nuyens; G Theilmeier; K Brusselmans; I Cornelissen; E Ehler; V V Kakkar; I Stalmans; V Mattot; J C Perriard; M Dewerchin; W Flameng; A Nagy; F Lupu; L Moons; D Collen; P A D'Amore; D T Shima
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity.

Authors:  Dirk L Brutsaert
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

3.  Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases.

Authors:  K Maruyama; Y Mori; S Murasawa; H Masaki; N Takahashi; Y Tsutusmi; Y Moriguchi; Y Shibazaki; Y Tanaka; M Shibuya; M Inada; H Matsubara; T Iwasaka
Journal:  J Mol Cell Cardiol       Date:  1999-03       Impact factor: 5.000

4.  Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.

Authors:  Y Fujio; K Walsh
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

5.  Verapamil normalizes the response of left ventricular early diastolic filling to cold pressor test in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  P P Dimitrow; A Surdacki; J S Dubiel
Journal:  Cardiovasc Drugs Ther       Date:  1997-12       Impact factor: 3.727

6.  Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart.

Authors:  Denise Hilfiker-Kleiner; Andres Hilfiker; Karol Kaminski; Arnd Schaefer; Joon-Keun Park; Kim Michel; Anja Quint; Moshe Yaniv; Jonathan B Weitzman; Helmut Drexler
Journal:  Circulation       Date:  2005-08-29       Impact factor: 29.690

7.  Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.

Authors:  Kou-Gi Shyu; Jer-Young Liou; Bao-Wei Wang; Wei-Jen Fang; Hang Chang
Journal:  J Biomed Sci       Date:  2005       Impact factor: 8.410

8.  A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function.

Authors:  F J Giordano; H P Gerber; S P Williams; N VanBruggen; S Bunting; P Ruiz-Lozano; Y Gu; A K Nath; Y Huang; R Hickey; N Dalton; K L Peterson; J Ross; K R Chien; N Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

9.  Adipose tissue mass can be regulated through the vasculature.

Authors:  Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

10.  Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth.

Authors:  Akihiro Takahashi; Yasuko Kureishi; Jiang Yang; Zhengyu Luo; Kun Guo; Debabrata Mukhopadhyay; Yuri Ivashchenko; Didier Branellec; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

View more
  127 in total

1.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

Review 2.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

4.  Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.

Authors:  Masayuki Shimano; Noriyuki Ouchi; Rei Shibata; Koji Ohashi; David R Pimentel; Toyoaki Murohara; Kenneth Walsh
Journal:  J Mol Cell Cardiol       Date:  2010-03-04       Impact factor: 5.000

Review 5.  AKT signalling in the failing heart.

Authors:  Antoine H Chaanine; Roger J Hajjar
Journal:  Eur J Heart Fail       Date:  2011-06-30       Impact factor: 15.534

6.  Wnt5a-Mediated Neutrophil Recruitment Has an Obligatory Role in Pressure Overload-Induced Cardiac Dysfunction.

Authors:  Ying Wang; Soichi Sano; Kosei Oshima; Miho Sano; Yosuke Watanabe; Yasufumi Katanasaka; Yoshimitsu Yura; Changhee Jung; Atsushi Anzai; Filip K Swirski; Noyan Gokce; Kenneth Walsh
Journal:  Circulation       Date:  2019-06-07       Impact factor: 29.690

7.  Short-term akt activation in cardiac muscle cells improves contractile function in failing hearts.

Authors:  Ichiro Shiojima; Stephan Schiekofer; Jochen G Schneider; Kurt Belisle; Kaori Sato; Martin Andrassy; Gennaro Galasso; Kenneth Walsh
Journal:  Am J Pathol       Date:  2012-09-30       Impact factor: 4.307

Review 8.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

Review 9.  Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease.

Authors:  David J Polhemus; David J Lefer
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

10.  Myocardial perfusion MRI shows impaired perfusion of the mouse hypertrophic left ventricle.

Authors:  Bastiaan J van Nierop; Bram F Coolen; Noortje A Bax; Wouter J R Dijk; Elza D van Deel; Dirk J Duncker; Klaas Nicolay; Gustav J Strijkers
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-28       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.